

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma

Information for the public

Published: 26 October 2022

www.nice.org.uk

Pembrolizumab (Keytruda) is available on the NHS as a possible adjuvant treatment for surgically removed stage 2B or 2C melanoma in people 12 years and over. An adjuvant treatment is one that is offered after surgery to lower the risk that the cancer will come back.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Melanoma UK](#), 0808 171 2455
- [Melanoma Focus](#), 01223 324359
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4811-6